These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26130783)

  • 1. Bedaquiline: finding the pores on the pot.
    Salfinger M; Migliori GB
    Eur Respir J; 2015 Jul; 46(1):289-91. PubMed ID: 26130783
    [No Abstract]   [Full Text] [Related]  

  • 2. Bedaquiline: finding the pores on the pot.
    Mohapatra PR
    Eur Respir J; 2015 Jul; 46(1):288-9. PubMed ID: 26130782
    [No Abstract]   [Full Text] [Related]  

  • 3. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
    Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC
    Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333
    [No Abstract]   [Full Text] [Related]  

  • 4. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending.
    Salfinger M; Migliori GB
    Eur Respir J; 2015 Feb; 45(2):317-21. PubMed ID: 25653264
    [No Abstract]   [Full Text] [Related]  

  • 5. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
    Olaru ID; Heyckendorf J; Andres S; Kalsdorf B; Lange C
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529207
    [No Abstract]   [Full Text] [Related]  

  • 8. Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Udwadia ZF; Ganatra S; Mullerpattan JB
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331036
    [No Abstract]   [Full Text] [Related]  

  • 9. Daily Dosing for Bedaquiline in Patients with Tuberculosis.
    Salinger DH; Nedelman JR; Mendel C; Spigelman M; Hermann DJ
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofazimine Exposure
    Ismail N; Peters RPH; Ismail NA; Omar SV
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique.
    Bastard M; Molfino L; Mutaquiha C; Galindo MA; Zindoga P; Vaz D; Mahinça I; DuCros P; Rusch B; Telnov A
    Clin Infect Dis; 2019 Oct; 69(10):1809-1811. PubMed ID: 30901021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
    Guglielmetti L; Barkane L; Le Dû D; Marigot-Outtandy D; Robert J; Veziris N; Yazdanpanah Y; Kuksa L; Caumes E; Fréchet-Jachym M
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29419439
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis.
    Akkerman OW; Odish OF; Bolhuis MS; de Lange WC; Kremer HP; Luijckx GJ; van der Werf TS; Alffenaar JW
    Clin Infect Dis; 2016 Feb; 62(4):523-4. PubMed ID: 26534926
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.
    Pontali E; Sotgiu G; Tiberi S; D'Ambrosio L; Centis R; Migliori GB
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29146605
    [No Abstract]   [Full Text] [Related]  

  • 16. Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
    Caminero JA; Piubello A; Scardigli A; Migliori GB
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28679614
    [No Abstract]   [Full Text] [Related]  

  • 17. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
    Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
    Caminero JA; Scardigli A
    Eur Respir J; 2015 Oct; 46(4):887-93. PubMed ID: 26424519
    [No Abstract]   [Full Text] [Related]  

  • 19. Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?
    Masini T; Hauser J; Kuwana R; Nhat Linh N; Jaramillo E
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29567722
    [No Abstract]   [Full Text] [Related]  

  • 20. Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.
    Andres S; Merker M; Heyckendorf J; Kalsdorf B; Rumetshofer R; Indra A; Hofmann-Thiel S; Hoffmann H; Lange C; Niemann S; Maurer FP
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1564-1568. PubMed ID: 32053752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.